If this pattern holds, future medications targeting four or more pathways could theoretically approach A1C reductions rivaling what some surgical interventions achieve
Compounded GLP-1 Medications (e.g
Long-acting agonists currently lead the market due to their convenience and efficacy in providing consistent blood glucose control with fewer injections
In 1992, the General Accounting Office (GAO)the historical predecessor to the Government Accountability Officereleased the report Womens Health: FDA Needs to Ensure More Study of Gender Differences in Prescription Drug Testing, ushering a new era of focus on the issue of diversity in clinical trials
Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation
Scientists soon found that GLP-1 had multiple metabolic benefits, including: Stimulating insulin release Suppressing glucagon (which raises blood sugar) Slowing gastric emptying (making you feel fuller longer) Reducing appetite and food intake Fast Forward It wasn't until the 2010s that researchers noticed Type 2 diabetes patients taking GLP-1 drugs lost weight, likely due to their effects on appetite suppression and slowed digestion
